APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026195 pages

Choose your research edition.

Industry ResearchVaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) include CNADC, Guangdong Yongshun Biological Pharmaceutical Co Ltd, Tiankang, Tianjin Ruipu Biological Technology Co., Ltd., Qilu Animal Health, Plec Bioengineering Co., Ltd., Jinyu Bio-Technology, Sinopharm and Guangdong Wens Dahuanong Biotechnology Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market size, projected growth trends, production technologies, key applications, and end-use industries.

Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Segment by Company

CNADC

Guangdong Yongshun Biological Pharmaceutical Co Ltd

Tiankang

Tianjin Ruipu Biological Technology Co., Ltd.

Qilu Animal Health

Plec Bioengineering Co., Ltd.

Jinyu Bio-Technology

Sinopharm

Guangdong Wens Dahuanong Biotechnology Co., Ltd.

Chengdu Tianbang Biological Products Co., Ltd.

Boehringer-Ingelheim

Zoetis

Phibro Animal Health

MSD Animal Health

Komipharm

Ceva

CAVAC

Bioveta

Agrovet

Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Segment by Type

Live Vaccine

Inactivated Vaccine

Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Segment by Application

Government Tender

Marketing

Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Trends Table 2. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Drivers Table 3. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Opportunities and Challenges Table 4. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Restraints Table 5. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Manufacturers Table 9. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Manufacturers, Product Type & Application Table 13. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Live Vaccine Table 17. Major Manufacturers of Inactivated Vaccine Table 18. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Type (2021-2026) & (K Units) Table 20. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Type (2027-2032) & (K Units) Table 21. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Type (2021-2026) Table 22. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Type (2027-2032) Table 23. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Type (2021-2026) & (K Units) Table 25. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Type (2027-2032) & (K Units) Table 26. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Type (2021-2026) Table 27. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Government Tender Table 29. Major Manufacturers of Marketing Table 30. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Application (2021-2026) & (K Units) Table 32. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Application (2027-2032) & (K Units) Table 33. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Application (2021-2026) Table 34. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Application (2027-2032) Table 35. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Application (2021-2026) & (K Units) Table 37. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Application (2027-2032) & (K Units) Table 38. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Application (2021-2026) Table 39. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Application (2027-2032) Table 40. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region (2021-2026) & (K Units) Table 42. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Region (2021-2026) Table 43. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2021-2026) & (K Units) Table 47. North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2027-2032) & (K Units) Table 48. Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2021-2026) & (K Units) Table 50. Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2027-2032) & (K Units) Table 57. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Region (2021-2026) Table 61. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Region (2027-2032) Table 62. CNADC Company Information Table 63. CNADC Business Overview Table 64. CNADC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. CNADC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 66. CNADC Recent Development Table 67. Guangdong Yongshun Biological Pharmaceutical Co Ltd Company Information Table 68. Guangdong Yongshun Biological Pharmaceutical Co Ltd Business Overview Table 69. Guangdong Yongshun Biological Pharmaceutical Co Ltd Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Guangdong Yongshun Biological Pharmaceutical Co Ltd Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 71. Guangdong Yongshun Biological Pharmaceutical Co Ltd Recent Development Table 72. Tiankang Company Information Table 73. Tiankang Business Overview Table 74. Tiankang Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Tiankang Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 76. Tiankang Recent Development Table 77. Tianjin Ruipu Biological Technology Co., Ltd. Company Information Table 78. Tianjin Ruipu Biological Technology Co., Ltd. Business Overview Table 79. Tianjin Ruipu Biological Technology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Tianjin Ruipu Biological Technology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 81. Tianjin Ruipu Biological Technology Co., Ltd. Recent Development Table 82. Qilu Animal Health Company Information Table 83. Qilu Animal Health Business Overview Table 84. Qilu Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Qilu Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 86. Qilu Animal Health Recent Development Table 87. Plec Bioengineering Co., Ltd. Company Information Table 88. Plec Bioengineering Co., Ltd. Business Overview Table 89. Plec Bioengineering Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Plec Bioengineering Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 91. Plec Bioengineering Co., Ltd. Recent Development Table 92. Jinyu Bio-Technology Company Information Table 93. Jinyu Bio-Technology Business Overview Table 94. Jinyu Bio-Technology Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Jinyu Bio-Technology Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 96. Jinyu Bio-Technology Recent Development Table 97. Sinopharm Company Information Table 98. Sinopharm Business Overview Table 99. Sinopharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Sinopharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 101. Sinopharm Recent Development Table 102. Guangdong Wens Dahuanong Biotechnology Co., Ltd. Company Information Table 103. Guangdong Wens Dahuanong Biotechnology Co., Ltd. Business Overview Table 104. Guangdong Wens Dahuanong Biotechnology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Guangdong Wens Dahuanong Biotechnology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 106. Guangdong Wens Dahuanong Biotechnology Co., Ltd. Recent Development Table 107. Chengdu Tianbang Biological Products Co., Ltd. Company Information Table 108. Chengdu Tianbang Biological Products Co., Ltd. Business Overview Table 109. Chengdu Tianbang Biological Products Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Chengdu Tianbang Biological Products Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 111. Chengdu Tianbang Biological Products Co., Ltd. Recent Development Table 112. Boehringer-Ingelheim Company Information Table 113. Boehringer-Ingelheim Business Overview Table 114. Boehringer-Ingelheim Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Boehringer-Ingelheim Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 116. Boehringer-Ingelheim Recent Development Table 117. Zoetis Company Information Table 118. Zoetis Business Overview Table 119. Zoetis Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Zoetis Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 121. Zoetis Recent Development Table 122. Phibro Animal Health Company Information Table 123. Phibro Animal Health Business Overview Table 124. Phibro Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Phibro Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 126. Phibro Animal Health Recent Development Table 127. MSD Animal Health Company Information Table 128. MSD Animal Health Business Overview Table 129. MSD Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. MSD Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 131. MSD Animal Health Recent Development Table 132. Komipharm Company Information Table 133. Komipharm Business Overview Table 134. Komipharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Komipharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 136. Komipharm Recent Development Table 137. Ceva Company Information Table 138. Ceva Business Overview Table 139. Ceva Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Ceva Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 141. Ceva Recent Development Table 142. CAVAC Company Information Table 143. CAVAC Business Overview Table 144. CAVAC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. CAVAC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 146. CAVAC Recent Development Table 147. Bioveta Company Information Table 148. Bioveta Business Overview Table 149. Bioveta Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Bioveta Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 151. Bioveta Recent Development Table 152. Agrovet Company Information Table 153. Agrovet Business Overview Table 154. Agrovet Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. Agrovet Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 156. Agrovet Recent Development Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Distributors List Table 160. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Image Figure 2. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Size (2021-2032) & (US$ Million) Figure 4. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (2021-2032) & (K Units) Figure 5. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Live Vaccine Image Figure 9. Inactivated Vaccine Image Figure 10. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Type (2021-2032) Figure 13. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Type (2021-2032) Figure 16. Government Tender Image Figure 17. Marketing Image Figure 18. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Application (2021-2032) Figure 21. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Application (2021-2032) Figure 24. North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Country (2021-2032) Figure 26. U.S. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Country (2021-2032) Figure 31. Germany Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Country (2021-2032) Figure 38. China Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Country (2021-2032) Figure 46. Brazil Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue (2021-2032) & (US$ Million) Figure 57. North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue (2021-2032) & (US$ Million) Figure 59. Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Live Vaccine
  • Inactivated Vaccine
Applications
  • Government Tender
  • Marketing
Companies covered
  • CNADC
  • Guangdong Yongshun Biological Pharmaceutical Co Ltd
  • Tiankang
  • Tianjin Ruipu Biological Technology Co., Ltd.
  • Qilu Animal Health
  • Plec Bioengineering Co., Ltd.
  • Jinyu Bio-Technology
  • Sinopharm
  • Guangdong Wens Dahuanong Biotechnology Co., Ltd.
  • Chengdu Tianbang Biological Products Co., Ltd.
  • Boehringer-Ingelheim
  • Zoetis
  • Phibro Animal Health
  • MSD Animal Health
  • Komipharm
  • Ceva
  • CAVAC
  • Bioveta
  • Agrovet

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Dynamics
  1. 2.1 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Trends
  2. 2.2 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Drivers
  3. 2.3 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Opportunities and Challenges
  4. 2.4 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Restraints
3 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market by Manufacturers
  1. 3.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Manufacturers, Product Type & Application
  7. 3.7 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Tier 1, Tier 2, and Tier 3
4 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market by Type
  1. 4.1 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Type Introduction
  2. 4.1.1 Live Vaccine
  3. 4.1.2 Inactivated Vaccine
  4. 4.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Type
  5. 4.2.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Type (2021-2032)
  7. 4.2.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Type (2021-2032)
  8. 4.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Type
  9. 4.3.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Type (2021-2032)
  11. 4.3.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Type (2021-2032)
5 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market by Application
  1. 5.1 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Application Introduction
  2. 5.1.1 Government Tender
  3. 5.1.2 Marketing
  4. 5.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Application
  5. 5.2.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Application (2021-2032)
  7. 5.2.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Application (2021-2032)
  8. 5.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Application
  9. 5.3.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Application (2021-2032)
  11. 5.3.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Application (2021-2032)
6 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region
  1. 6.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region (2021-2032)
  3. 6.2.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region (2021-2026)
  4. 6.2.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Region
  1. 7.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Region
  2. 7.1.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Region (2021-2026)
  4. 7.1.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Region (2027-2032)
  5. 7.1.4 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue (2021-2032)
  8. 7.2.2 North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue (2021-2032)
  11. 7.3.2 Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CNADC
  2. 8.1.1 CNADC Company Information
  3. 8.1.2 CNADC Business Overview
  4. 8.1.3 CNADC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CNADC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  6. 8.1.5 CNADC Recent Developments
  7. 8.2 Guangdong Yongshun Biological Pharmaceutical Co Ltd
  8. 8.2.1 Guangdong Yongshun Biological Pharmaceutical Co Ltd Company Information
  9. 8.2.2 Guangdong Yongshun Biological Pharmaceutical Co Ltd Business Overview
  10. 8.2.3 Guangdong Yongshun Biological Pharmaceutical Co Ltd Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Guangdong Yongshun Biological Pharmaceutical Co Ltd Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  12. 8.2.5 Guangdong Yongshun Biological Pharmaceutical Co Ltd Recent Developments
  13. 8.3 Tiankang
  14. 8.3.1 Tiankang Company Information
  15. 8.3.2 Tiankang Business Overview
  16. 8.3.3 Tiankang Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Tiankang Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  18. 8.3.5 Tiankang Recent Developments
  19. 8.4 Tianjin Ruipu Biological Technology Co., Ltd.
  20. 8.4.1 Tianjin Ruipu Biological Technology Co., Ltd. Company Information
  21. 8.4.2 Tianjin Ruipu Biological Technology Co., Ltd. Business Overview
  22. 8.4.3 Tianjin Ruipu Biological Technology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Tianjin Ruipu Biological Technology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  24. 8.4.5 Tianjin Ruipu Biological Technology Co., Ltd. Recent Developments
  25. 8.5 Qilu Animal Health
  26. 8.5.1 Qilu Animal Health Company Information
  27. 8.5.2 Qilu Animal Health Business Overview
  28. 8.5.3 Qilu Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Qilu Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  30. 8.5.5 Qilu Animal Health Recent Developments
  31. 8.6 Plec Bioengineering Co., Ltd.
  32. 8.6.1 Plec Bioengineering Co., Ltd. Company Information
  33. 8.6.2 Plec Bioengineering Co., Ltd. Business Overview
  34. 8.6.3 Plec Bioengineering Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Plec Bioengineering Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  36. 8.6.5 Plec Bioengineering Co., Ltd. Recent Developments
  37. 8.7 Jinyu Bio-Technology
  38. 8.7.1 Jinyu Bio-Technology Company Information
  39. 8.7.2 Jinyu Bio-Technology Business Overview
  40. 8.7.3 Jinyu Bio-Technology Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jinyu Bio-Technology Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  42. 8.7.5 Jinyu Bio-Technology Recent Developments
  43. 8.8 Sinopharm
  44. 8.8.1 Sinopharm Company Information
  45. 8.8.2 Sinopharm Business Overview
  46. 8.8.3 Sinopharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sinopharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  48. 8.8.5 Sinopharm Recent Developments
  49. 8.9 Guangdong Wens Dahuanong Biotechnology Co., Ltd.
  50. 8.9.1 Guangdong Wens Dahuanong Biotechnology Co., Ltd. Company Information
  51. 8.9.2 Guangdong Wens Dahuanong Biotechnology Co., Ltd. Business Overview
  52. 8.9.3 Guangdong Wens Dahuanong Biotechnology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Guangdong Wens Dahuanong Biotechnology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  54. 8.9.5 Guangdong Wens Dahuanong Biotechnology Co., Ltd. Recent Developments
  55. 8.10 Chengdu Tianbang Biological Products Co., Ltd.
  56. 8.10.1 Chengdu Tianbang Biological Products Co., Ltd. Company Information
  57. 8.10.2 Chengdu Tianbang Biological Products Co., Ltd. Business Overview
  58. 8.10.3 Chengdu Tianbang Biological Products Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Chengdu Tianbang Biological Products Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  60. 8.10.5 Chengdu Tianbang Biological Products Co., Ltd. Recent Developments
  61. 8.11 Boehringer-Ingelheim
  62. 8.11.1 Boehringer-Ingelheim Company Information
  63. 8.11.2 Boehringer-Ingelheim Business Overview
  64. 8.11.3 Boehringer-Ingelheim Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer-Ingelheim Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  66. 8.11.5 Boehringer-Ingelheim Recent Developments
  67. 8.12 Zoetis
  68. 8.12.1 Zoetis Company Information
  69. 8.12.2 Zoetis Business Overview
  70. 8.12.3 Zoetis Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Zoetis Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  72. 8.12.5 Zoetis Recent Developments
  73. 8.13 Phibro Animal Health
  74. 8.13.1 Phibro Animal Health Company Information
  75. 8.13.2 Phibro Animal Health Business Overview
  76. 8.13.3 Phibro Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Phibro Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  78. 8.13.5 Phibro Animal Health Recent Developments
  79. 8.14 MSD Animal Health
  80. 8.14.1 MSD Animal Health Company Information
  81. 8.14.2 MSD Animal Health Business Overview
  82. 8.14.3 MSD Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 MSD Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  84. 8.14.5 MSD Animal Health Recent Developments
  85. 8.15 Komipharm
  86. 8.15.1 Komipharm Company Information
  87. 8.15.2 Komipharm Business Overview
  88. 8.15.3 Komipharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Komipharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  90. 8.15.5 Komipharm Recent Developments
  91. 8.16 Ceva
  92. 8.16.1 Ceva Company Information
  93. 8.16.2 Ceva Business Overview
  94. 8.16.3 Ceva Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Ceva Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  96. 8.16.5 Ceva Recent Developments
  97. 8.17 CAVAC
  98. 8.17.1 CAVAC Company Information
  99. 8.17.2 CAVAC Business Overview
  100. 8.17.3 CAVAC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 CAVAC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  102. 8.17.5 CAVAC Recent Developments
  103. 8.18 Bioveta
  104. 8.18.1 Bioveta Company Information
  105. 8.18.2 Bioveta Business Overview
  106. 8.18.3 Bioveta Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Bioveta Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  108. 8.18.5 Bioveta Recent Developments
  109. 8.19 Agrovet
  110. 8.19.1 Agrovet Company Information
  111. 8.19.2 Agrovet Business Overview
  112. 8.19.3 Agrovet Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Agrovet Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  114. 8.19.5 Agrovet Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Value Chain Analysis
  2. 9.1.1 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Production Mode & Process
  6. 9.2 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Distributors
  9. 9.2.3 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst